



UBIFRANCE
NORTH AMERICA

"PARTNERING WITH FRANCE" WORKSHOP
Tuesday February 26th from 1.30pm to 2.30pm
Room #122

Opening remarks:

Mr. Jean-Pascal Saucier - Director Business Development, Invest in France Agency



Dr. Prakash Purohit - Director, Scientific Affairs, US/NA, IPSEN PHARMA



"Innovation in Patient Care Through Partnering"

Workshop Moderator: Dr. Prakash Purohit - Director, Scientific Affairs, US/NA, IPSEN PHARMA

Speakers:



Ms. Nadège Prel – Business Development Manager, Affilogic

Affilogic is a biotech company developing a new class of affinity ligands, Nanofitins[®], as a robust and affordable alternative to antibodies. The idea is to develop drugs with routes of administration that couldn't be reached by antibodies because of their size/instability. Affilogic is currently engaged in Inflammation, CNS, Ophthalmology and Infectiology and assessing oral administration, crossing of BBB, skin permeation, cornea penetration.



Dr. Emmanuel Dejean – President & CEO, Calixar / Dr. Anass Jawhari – CSO, Calixar

Calixar offers a patented technological platform allowing expression, extraction, purification and stabilization of full-length membrane proteins (GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins) in solution, while keeping their structural and functionality integrity (without refolding steps and avoiding mutagenesis). The native protein targets can be expressed in various systems such as cell free, E.coli, yeast, insect cells, CHO or HEK cells. The extraction can be also carried out from biological material (cells or organs). We provide a range of R&D services including identification, expression, extraction, purification, stabilisation as well as crystallization of the target. Our deliverables are detailed reports with protocols, sets of targets stabilized in solution for HTS, antibody production, crystallization trials or for protein/protein interactions studies.



Dr. Patrick Dutartre – President, Cohiro

Cohiro is a private independent CRO who helps you if you are concerned by inflammation and oxidative stress in human or animals. Laboratory approaches are available for the optimization and /or development of drug extracts, industrial processes industrial byproducts, and marketed final products. Cohiro provides know-how for the demonstration of health claims, definition of pharmacology, safety profile, and mechanism of action. Located in university facilities at the interface between fundamental and applied research with a direct link to clinical studies, Cohiro provides expertise respecting GLP for the pharmaceutical cosmetics field OTC food supplements, healthy food and veterinary.



Dr Gabriel Baverel – CEO, Metabolys

Metabolys has a mixed business model.

- On the one hand, Metabolys utilizes cellular metabolomics (or metabolic flux analysis) to predict the safety and efficacy of milligram amounts of drug candidates. This approach, which significantly reduces the risk, time and cost of the drug development process, is also used for establishing the metabolic characteristics of cancer cells and cell lines in culture.
- On the other hand, Metabolys has a drug discovery line in the diabetes field. One patented, optimized and promising antidiabetic candidate is being developed and will be out-licensed.



M. Frederic Legros – Business Development, Director, Vivalis

Vivalis offers a cutting-edge solution for the discovery of extremely rare monoclonal antibodies, with a high therapeutic value, isolated from individual human B-lymphocytes. This technology relies on the access to a large panel of human blood donors to select those with the highest and most potent antibody response against a particular target and on an efficient, massive in vitro culture and screening of primary B-lymphocytes for the secretion of antibodies of therapeutic relevance. Using its high throughput, single-cell screening system based on a proprietary micro-array chip technology, our platform allows rapid and precise mass screening of millions of B-lymphocytes. Thus, the identification of extremely rare and active monoclonal antibodies across multiple indications, including oncology, anti-inflammatory conditions, and infectious disease is now achievable.